The effect of oral prostaglandin analogue on painful diabetic neuropathy: A double-blind, randomized, controlled trial

S. Shin, K. J. Kim, H. J. Chang, B. W. Lee, W. I. Yang, B. S. Cha, D. Choi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This study was performed to assess the efficacy of beraprost sodium (BPS) in painful diabetic peripheral neuropathy (DPN) in type 2 diabetes mellitus (T2DM) patients. In this randomized clinical trial, 99 T2DM patients (41% male, age 60±6years) with DPN but without evidence of peripheral artery disease were randomized to receive either BPS (40 μg, tid) or placebo for 8weeks. The primary end point was the improvement of the total symptom score (TSS), temperature rebound (TR) and nadir to peak (NP) above baseline. After 8weeks treatment, the change of TSS in the BPS group showed a significant improvement compared to the placebo group (2.80±2.48 vs. 1.60±1.94 points, p=0.009). Furthermore, the number of patients who showed signs of improvement in TSS and the proportion of patients with 50% relief of symptom was also significantly greater in the BPS group than in the placebo group (83.7 vs. 62%, p=0.015, 36.2 vs. 14%, p=0.009, respectively). In conclusion, treatment with BPS significantly improved TSS over an 8-week period.

Original languageEnglish
Pages (from-to)185-188
Number of pages4
JournalDiabetes, Obesity and Metabolism
Volume15
Issue number2
DOIs
Publication statusPublished - 2013 Feb

Fingerprint

beraprost
Synthetic Prostaglandins
Diabetic Neuropathies
Randomized Controlled Trials
Placebos
Peripheral Nervous System Diseases
Type 2 Diabetes Mellitus
Peripheral Arterial Disease

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{1f2a29d602404a00b83b58d07563e11d,
title = "The effect of oral prostaglandin analogue on painful diabetic neuropathy: A double-blind, randomized, controlled trial",
abstract = "This study was performed to assess the efficacy of beraprost sodium (BPS) in painful diabetic peripheral neuropathy (DPN) in type 2 diabetes mellitus (T2DM) patients. In this randomized clinical trial, 99 T2DM patients (41{\%} male, age 60±6years) with DPN but without evidence of peripheral artery disease were randomized to receive either BPS (40 μg, tid) or placebo for 8weeks. The primary end point was the improvement of the total symptom score (TSS), temperature rebound (TR) and nadir to peak (NP) above baseline. After 8weeks treatment, the change of TSS in the BPS group showed a significant improvement compared to the placebo group (2.80±2.48 vs. 1.60±1.94 points, p=0.009). Furthermore, the number of patients who showed signs of improvement in TSS and the proportion of patients with 50{\%} relief of symptom was also significantly greater in the BPS group than in the placebo group (83.7 vs. 62{\%}, p=0.015, 36.2 vs. 14{\%}, p=0.009, respectively). In conclusion, treatment with BPS significantly improved TSS over an 8-week period.",
author = "S. Shin and Kim, {K. J.} and Chang, {H. J.} and Lee, {B. W.} and Yang, {W. I.} and Cha, {B. S.} and D. Choi",
year = "2013",
month = "2",
doi = "10.1111/dom.12010",
language = "English",
volume = "15",
pages = "185--188",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "2",

}

The effect of oral prostaglandin analogue on painful diabetic neuropathy : A double-blind, randomized, controlled trial. / Shin, S.; Kim, K. J.; Chang, H. J.; Lee, B. W.; Yang, W. I.; Cha, B. S.; Choi, D.

In: Diabetes, Obesity and Metabolism, Vol. 15, No. 2, 02.2013, p. 185-188.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of oral prostaglandin analogue on painful diabetic neuropathy

T2 - A double-blind, randomized, controlled trial

AU - Shin, S.

AU - Kim, K. J.

AU - Chang, H. J.

AU - Lee, B. W.

AU - Yang, W. I.

AU - Cha, B. S.

AU - Choi, D.

PY - 2013/2

Y1 - 2013/2

N2 - This study was performed to assess the efficacy of beraprost sodium (BPS) in painful diabetic peripheral neuropathy (DPN) in type 2 diabetes mellitus (T2DM) patients. In this randomized clinical trial, 99 T2DM patients (41% male, age 60±6years) with DPN but without evidence of peripheral artery disease were randomized to receive either BPS (40 μg, tid) or placebo for 8weeks. The primary end point was the improvement of the total symptom score (TSS), temperature rebound (TR) and nadir to peak (NP) above baseline. After 8weeks treatment, the change of TSS in the BPS group showed a significant improvement compared to the placebo group (2.80±2.48 vs. 1.60±1.94 points, p=0.009). Furthermore, the number of patients who showed signs of improvement in TSS and the proportion of patients with 50% relief of symptom was also significantly greater in the BPS group than in the placebo group (83.7 vs. 62%, p=0.015, 36.2 vs. 14%, p=0.009, respectively). In conclusion, treatment with BPS significantly improved TSS over an 8-week period.

AB - This study was performed to assess the efficacy of beraprost sodium (BPS) in painful diabetic peripheral neuropathy (DPN) in type 2 diabetes mellitus (T2DM) patients. In this randomized clinical trial, 99 T2DM patients (41% male, age 60±6years) with DPN but without evidence of peripheral artery disease were randomized to receive either BPS (40 μg, tid) or placebo for 8weeks. The primary end point was the improvement of the total symptom score (TSS), temperature rebound (TR) and nadir to peak (NP) above baseline. After 8weeks treatment, the change of TSS in the BPS group showed a significant improvement compared to the placebo group (2.80±2.48 vs. 1.60±1.94 points, p=0.009). Furthermore, the number of patients who showed signs of improvement in TSS and the proportion of patients with 50% relief of symptom was also significantly greater in the BPS group than in the placebo group (83.7 vs. 62%, p=0.015, 36.2 vs. 14%, p=0.009, respectively). In conclusion, treatment with BPS significantly improved TSS over an 8-week period.

UR - http://www.scopus.com/inward/record.url?scp=84871937278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871937278&partnerID=8YFLogxK

U2 - 10.1111/dom.12010

DO - 10.1111/dom.12010

M3 - Article

C2 - 22974254

AN - SCOPUS:84871937278

VL - 15

SP - 185

EP - 188

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 2

ER -